$30 Billion Deal, page-4424

First 4424 Last

Share
Profile

Follow
numbnuts01

632 Posts.

99

27/02/24

11:47

Post #: 72616811
Share
Originally posted by thorndog: ↑

I've reached out to Michelle again with some questions.
Hi Michelle,

Reading through the Half Yearly Report the terminology around "Release of headline results is expected in coming weeks" which has been stated since September 2023. Though that outcome stated, there appear to be a number of key milestones that would need to be achieved which have no visible or tangible completion dates, those being:
Completion of clinical trial data by the external Contract Research Organisations. I can appreciate this is somewhat out of Biotrons control as stated, though I would expect that the Directors can request (demand) a forecast completion date which can then be communicated to the shareholder community.
Once the data is received, Biotron has stated the following actions will be taken - "the trial database will be locked, the data unblinded and statistical analyses of the data can be completed.". This I would expect can have milestones stated based on a forecast completion from the CROs, along with the experience and knowledge of the post-clinical trial analysis tasks within the Biotron leadership team and biotech industry standards, even if it's just Results + x Months = Milestone y. Again this level of forecast schedule information would be well received by the Biotron shareholder community.
In the last quarterly update the operational cash available was unsustainable to operate for another quarter though the R&D rebate has at least given a little buffer for funding operations. Though that said, I would expect the ongoing delays will be costing Biotron and without forecast dates from points 1 and 2 it seems that Biotron will either be unfunded to continue operations or require a capital raise before May/June, yet the December quarterly indicated neither of these will be needed. This is concerning and it would be good if Biotron provided a path to solve this question.
Thanks for your time.

Expand

I hope that MnM replies to your email.

Though she probably has a pre scripted email for a standard reply as no sensative info could be sent out.

It is a shame the SP is back where it is.

SHs need an updated timeline
BIT Price at posting: 7.4¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 655 more messages in this thread...

First 4424 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 5.6¢		Change 0.000(0.00%)		Mkt cap ! $50.52M

Open	High	Low	Value	Volume
5.7¢	5.7¢	5.6¢	$11.28K	200K

Buyers (Bids)

No.	Vol.	Price($)
3	117596	5.6¢

Sellers (Offers)

Price($)	Vol.	No.
5.9¢	167018	2

View Market Depth

No.	Vol.	Price($)
3	117596	0.056
4	82119	0.054
3	768657	0.053
4	485247	0.052
5	583888	0.051

Price($)	Vol.	No.
0.059	167018	2
0.060	461322	4
0.063	105621	2
0.065	46045	3
0.068	25200	2

Last trade - 10.00am 04/06/2024 (20 minute delay)

BIT (ASX) Chart

$30 Billion Deal, page-4424

Featured News

Kincora secures untested porphyry project Wongarbon in prime territory

Daily ASX Market Open: Commodity prices to weigh | June 4, 2024

Drilling doubles gold-copper mineralisation zone at GEO-01 for Antipa

Infini boosts WA uranium holdings with Bellah Bore East acquisition

Immutep targets $100m for lung cancer drug trial tests

Buyers (Bids)

Sellers (Offers)

Featured News

$30 Billion Deal, page-4424

Featured News

Top Stories

Kincora secures untested porphyry project Wongarbon in prime territory

Daily ASX Market Open: Commodity prices to weigh | June 4, 2024

Drilling doubles gold-copper mineralisation zone at GEO-01 for Antipa

Infini boosts WA uranium holdings with Bellah Bore East acquisition

Immutep targets $100m for lung cancer drug trial tests

Buyers (Bids)

Sellers (Offers)

Featured News